Understanding a New Zebrafish Publication on Levocarnitine
Post authored by: Jeff Cottrell, PhD, Morgan Weberg, BS, and Melody Kisor, MS, BCPA A recent research study published in
April 2026 – Updates on the SCN2A Drug Development Pipeline
Dear SCN2A Community, Everything starts with a committed and engaged community. The trust you place in us to share updates,
Reflections from AES: Collaboration, Momentum, and What’s Ahead for SCN2A
Photo: Jeff Cottrell – Interim Chief Scientific Officer, Leah Myers – Executive Director, Angie Weaver – Director of Philanthropy & Development, Amanda Gale –
Updates on the SCN2A Clinical Trial and Treatment Pipeline
The FamilieSCN2A Team: Amanda Gale – Program Manager, Angie Weaver – Director of Philanthropy & Development, Leah Myers – Executive
The FamilieSCN2A Foundation Response to Recent Autism News
“In light of this week’s public comments and media discussion about the causes and management of autism, we want you…
What to Expect When Considering a Clinical Trial: Clinical Research 101
Thinking about participating in a clinical trial, but not sure what it really means for your child and your family?
From Advocacy to Action: SCN2A Now Has Its Own ICD-10 Code
The FamilieSCN2A Foundation is thrilled to announce that advocacy efforts with the CDC over the last four years have resulted
What Baby KJ’s Breakthrough Means to Us
Town Hall Presentation by Shawn Egan, PhD and CSO, which is recorded here: Click Here There is excitement in the rare
AES 2024 Recap: Collaboration, Innovation, and Progress in Epilepsy Research
The 2024 American Epilepsy Society (AES) Annual Meeting was a dynamic gathering of clinicians, researchers, advocates, and caregivers committed to
Everlee’s Story: A Family’s Journey of Strength, Love, and Hope
The story of Everlee Robles is one of strength, love, and the unbreakable bond that holds a family together in